Android app Apple app link

Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug

By Yahoo! Finance   |   2 months ago
Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug

Novo Nordisk petitioned the FDA to exclude liraglutide from the 503B Bulks List, arguing that approved products meet patient needs, while compounded versions pose risks. The company warns of safety concerns and advocates for restricting unapproved drugs.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.